Interim

Cell Therapeutics, Inc. Management to Discuss Today's Announcement of Interim Pixantrone Study Results

SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- On Wednesday,July 11, 2007, at 1:30 p.m. Pacific/4:30 p.m. Eastern/10:30 p.m.Central European Time members of Cell Therapeutics, Inc.'s (CTI)management team will host a conference call to discuss today'sannouncement of the interim results of its phase II/III RAPID trialcomparing CHOP-R to CPOP-R, in which pixantrone is substituted fordoxor...

Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology

LUGANO, Switzerland--(BUSINESS WIRE)--Jul 9, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announces that positive interim datafrom an ongoing phase II trial of ZIO-201 (isophosphoramide mustard- IPM) to treat advanced sarcoma patients was presented at theEuropean Society of Medical Oncology (ESMO) meeting held July 5-8,2007 in Lugano, Switzerland. The abstract entitled, "Phase-I/IIStudy of...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced today the presentation of twoposters at the XIth Annual International Myeloma Workshop beingheld in Kos, Greece from June 25-28th, 2007. The meeting highlightsimportant advances made in the biology and treatment of multiplemyeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) geneexpression profil...

Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis

TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - AccentiaBiopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,June 27 at the Jefferies Healthcare Conference that its interimanalysis of the blinded data on the first fifty patients in theFast-Tracked Phase 3 clinical study of SinuNase(TM), at 8 weekspost-randomization, has demonstrated substantial improvement inresolution of one or both...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial

-- 46% of Evaluable Patients Show Stabilized Disease; BiomarkersCorrelate with Clinical Effect and Demonstrate Potential forPatient Stratification -- GERMANTOWN, Md., June 19, 2007 /PRNewswire-FirstCall/ -- AvalonPharmaceuticals, Inc. , today announced continued positive interimresults from its Phase I study of AVN944, for the treatment ofhematologic malignancies in elderly and refractory...

Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedical's Electroporation DNA Delivery Technology

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today that thecompany's partner, Vical Incorporated, presented positive interimsafety and tolerability data on 18 subjects from an ongoing Phase Iclinical trial...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...

Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancerand in Hormone-Refractory Prostate Cancer in Q307 - SOUTH SAN FRANCISCO, Calif., June 01, 2007/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , abiopharmaceutical company focused on oncology, today announcedpromising results from an interim safety analysis of two Phase 1dose-escalating trials of picoplatin, a new ge...

Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead ResearchCorporation (Nasdaq:ARWR) announced today that interim Phase I datahas been published in the 2007 American Society for ClinicalOncology Proceedings (ASCO) (Abstract ID 32638). The data are froman ongoing Phase I clinical study designed to evaluate the safety,tolerability, and pharmacokinetics of its lead anti-cancer drugcand...

Innovive Pharmaceuticals to Present Interim Data from Phase I Study of INNO-406 at the American Society of Clinical Oncology Annual Meeting

NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec(R)-resistant ortreatment-intolerant chronic myelogenous leukemia, will bepresented at the 43rd American Society of Clinical Oncology AnnualMeeting. The meeting takes pl...

Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results

SAN DIEGO--(BUSINESS WIRE)--May 24, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA-based DNAvaccines for cancers and infectious diseases and a novelalternative to surgery to treat localized cancers, announced todaythat interim clinical trial results demonstrated that a DNA-basedimmunotherapy delivered by Inovio's electroporation technology wassafe and tole...

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial

EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.today announced the audited three month results, reviewed by theData Monitoring Committee, of the first third of the patientstreated in its Phase 2b de novo kidney transplant trial for theCompany's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first116 patients enrolled....

PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy

Data Presented at 59th American Academy of Neurology Annual Meeting BOSTON and SOUTH PLAINFIELD, N.J., May 04, 2007 /PRNewswire/ --PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focusedon the discovery and development of small-molecule drugs targetingpost-transcriptional control processes, today announced positiveinterim data from a Phase 2 clinical trial of PTC124 in patientsw...

Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease

SAN DIEGO, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, Inc.today presented interim clinical data from a Phase 1 trial ofCERE-110, a gene therapy product designed to deliver nerve growthfactor (NGF) for the treatment of Alzheimer's disease. After oneyear of follow-up, the results for the six patients who receivedCERE-110 in the trial indicate that a single administration of thetherapy...

Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN

Interim analysis of Phase 2 comparative study showed significantresults in favor of alemtuzumab versus Rebif CAMBRIDGE, Mass. and WAYNE, N.J., May 02, 2007/PRNewswire-FirstCall/ -- Genzyme Corporation and Bayer HealthCarePharmaceutical today announced detailed interim results from theCAMMS223 Phase 2 study. This interim analysis of all patient datathrough at least twenty-four months from...

Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announcedthat an interim report regarding the clinical study of BF-200 ALAin actinic keratosis was received today from an independent reviewcommittee. The objectives of the study are to investigate theefficacy and safety of several doses of BF-200 ALA in photodynamictherapy. The comments received today refer to the clinical resultseight...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breakerpresentation at the 42nd Annual Meeting of the European Associationfor the Study of the Liver (EASL), researchers today presented datafrom a planned interim analysis of the PROVE 1 clinical trial,which is the first trial to evaluate short-duration therapy withthe investigational hepatitis C protease inhibitor telaprevir (TVR,...

Nasulin Interim Results to Be Presented at American Diabetes Association Scientific Sessions

EXETER, N.H.--(BUSINESS WIRE)--Apr 10, 2007 - BentleyPharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceuticalcompany, today announced that its abstract entitled "InterimResults of a Randomized, Single-Dose, 4-Way Crossover,Pharmacokinetic Study of Intranasal Insulin Spray (Nasulin(TM)),Injectable Regular Insulin (Humulin R(R)), Injectable Fast-ActingInsulin (Humalog(R)), and Saline Nas...

Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration

TARRYTOWN, N.Y. & LEVERKUSEN, Germany--(BUSINESS WIRE)--Mar 27,2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and BayerHealthCare AG (NYSE: BAY) today announced positive preliminary datafrom a pre-planned interim analysis of a Phase 2 randomized studyof their VEGF Trap-Eye in patients with the neovascular form ofage-related macular degeneration (wet AMD). The VEGF Trap-Eye metits...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced updated interim antibodyreduction data for the Phase 3 trial of Riquent(R) (abetimussodium), its drug candidate for systemic lupus erythematosus("lupus" or "SLE"). The updated analyses reinforce the previousconclusion that there is a definitive and significant dose responsebetween the 100 m...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodiesto Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced positive interim antibodyresults from its ongoing double-blind, placebo-controlledrandomized Phase 3 trial of Riquent(R) (abetimus sodium), its drugcandidate for systemic lupus erythematosus ("lupus" or "...